In a recent preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in ...
Early laboratory studies show that 77A can restore sensitivity to therapy in blood cancers, including multiple myeloma and lymphoma, as well as in certain solid tumors, where resistance remains a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results